Business

Knight Therapeutics Announces Regulatory Submission of GEMTESA® in Canada

Financial Post · September 15, 2026 at 7:34 a.m.

MONTREAL, Sept.

15, 2026 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (“Knight”) (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today that Knight’s New Drug Submission (NDS) for GEMTESA® (vibegron),

Read the full article on Financial Post ›

5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on financialpost.com — the content belongs to Financial Post.

Knight Therapeutics Announces Regulatory Submission of GEMTESA® in Canada

More from Financial Post

Flame collected in Turin as Changchun prepares to welcome 2027 Winter Universiade

PALESTINIAN REFORM ADVOCATE SAMER SINIJLAWI TELLS THE NEWS FORUM: ‘88% of eligible Palestinian voters have already preregistered for the November 28th election — the first election since 2005’

ModelFront Announces OpenLoc, the Open TMS Built for AI

PRU Quarterly Report Investor Webinar

More in Business

Canada can't launch rockets on its own. A handful of companies want to change that

Flame collected in Turin as Changchun prepares to welcome 2027 Winter Universiade

PALESTINIAN REFORM ADVOCATE SAMER SINIJLAWI TELLS THE NEWS FORUM: ‘88% of eligible Palestinian voters have already preregistered for the November 28th election — the first election since 2005’

ModelFront Announces OpenLoc, the Open TMS Built for AI

PRU Quarterly Report Investor Webinar

EasyPark Receives Three Awards at Canadian Parking Association Conference